In Brief: Ciba Tegretol XR
Executive Summary
Ciba Tegretol XR: Carbamazepine extended-release tablets available for first-line treatment of partial, secondarily generalized and generalized tonic-clonic epileptic seizures. The anticonvulsant, approved March 25, will be available in 100, 200 and 400 mg tablets for twice-daily dosing. The previous version of Tegretol required three to four daily doses. Dizziness, drowsiness, unsteadiness, nausea and vomiting are most frequently observed adverse events with Tegretol formulations, the company says...